Abstract 1440P
Background
Apatinib, a selective inhibitor of VEGFR2, showed a synergistic effect when combined with camrelizumab and chemotherapy in advanced esophageal squamous cell carcinoma (ESCC). We aim to assess the efficacy and safety of using the combination of camrelizumab with apatinib and chemotherapy as the neoadjuvant therapy for ESCC.
Methods
Patients with untreated, resectable (stage II or III) ESCC were enrolled. Each patient received two 21-day cycles of neoadjuvant treatment with intravenous camrelizumab, albumin-paclitaxel, carboplatin on day 1, and oral apatinib on days 1-14, followed by the third cycle without apatinib. The primary end point was pathological complete response (PCR). Secondary endpoints included safety, objective response rate (ORR) and disease control rate (DCR).
Results
Between February 2022 and November 2023, 70 eligible patients were enrolled. Three patients discontinued the treatment due to toxicity and 67 patients have completed the full three-cycle treatment. The ORR and DCR were 89.3% and 100%, respectively. 60 (85.7%) patients underwent surgery, and R0 resection was achieved in all cases. PCR was identified in 25 (41.6%) patients, and 5 (8.3%) patients had complete response of the primary tumor but residual disease in lymph nodes alone. Grade 3 or 4 trAEs included neutropenia (57.8%), leukopenia (55.2%), thrombocytopenia (28%), hepatitis (14.2%), febrile neutropenia (12.4%), hypertension (8.6%), and rash (4.2%). The median follow-up was 18.76 months and the 1-year DFS and OS rate was 90% and 95.7%. In prespecified exploratory biomarker analysis, PCR group exhibited elevated infiltrating cytotoxic T cells and effector memory T cells compared to the non-pCR group. Increased abundance of mature tertiary lymphoid structures was associated with PCR.
Conclusions
Neoadjuvant camrelizumab combined with apatinib and chemotherapy in patients with resectable ESCC achieved a high PCR rate (41.6%) and manageable trAEs. Larger cohorts are needed to examine whether this regimen is superior to that of camrelizumab combined with chemotherapy only regarding PCR and long-term survival.
Clinical trial identification
ChiCTR2100051763.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Institutional funding of First Affiliated Hospital of SUMS.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1525P - Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Presenter: Jens Siveke
Session: Poster session 18
1527P - GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)
Presenter: Satoshi Kobayashi
Session: Poster session 18
1528P - TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
Presenter: Yung-yeh Su
Session: Poster session 18
1531TiP - TWINPEAK phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC
Presenter: Michael Overman
Session: Poster session 18
1532TiP - Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
Presenter: Wungki Park
Session: Poster session 18
1533TiP - A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
Presenter: Xiaofei Zhang
Session: Poster session 18
1534TiP - Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
Presenter: Alfredo Budillon
Session: Poster session 18